The Wendel group investigates the molecular pathogenesis of lymphoma and develops experimental therapies. The hypothesis is that the same genetic lesions that promote malignant growth also create vulnerabilities and opportunities for tumor selective therapies.

We pursue both disease-centric lymphoma research and basic discovery research into the fundamental mechanisms of translational control in cancer. We use all tools of molecular biology, disease modeling in vivo, immune- and iPS-cell engineering, and high-throughput approaches in RNA sequencing, Crispr/Cas mutagenesis, and genetic screens. Collaborations with drug markers further enable us to develop and test new therapeutic strategies.

Learn more
Pictured: Hans-Guido Wendel

Hans-Guido Wendel, MD

Associate Member

Associate Professor

Research Focus

Cancer biologist Hans-Guido Wendel pursues both disease-centered and basic discovery research. The disease focus is on lymphocyte malignancies and the basic science arm of the lab explores fundamental mechanisms that control aberrant mRNA translation programs in cancer. Work in these two research areas frequently intersects in surprising ways.


  • Medical School of the Technical University of Aachen, Germany.
  • Medical School of the University of Edinburgh, UK.
  • Residency in Internal Medicine, University of Aachen, Germany.
  • Postdoctoral research at Cold Spring Harbor Laboratory

Lab Members


Learn more

Selected Achievements

  • Generation of CAR-T cells that produce anti-tumor proteins (“Micro-pharmacies”) (Cell 2016).
  • Identification of the HVEM – BTLA interaction as a major failsafe mechanism against lymphoma development (Cell 2016).  
  • Characterization of the key epigenetic regulators in lymphoma biology (MLL2/KMT2D and CREBBP/EP300) (Nature medicine 2015, Cancer discovery 2016).
  • Identification of an eIF4A dependent mechanism that controls the translation of G-quadruplex containing mRNAs including oncoproteins (Nature 2014).
  • Development of a rational combination therapy for high-risk follicular lymphoma (Journal of experimental medicine, 2014).
Read more
  • Generation of a cell engineering strategy to enhance the safe use of stem cells for therapy (Cell reports, 2014).
  • Identification and therapeutic delivery of the soluble tumor suppressor EphA7 in lymphoma (Cell 2011).
  • Identification of MNK kinase as a cancer drug target (Genes & development 2009).
  • Identification of the oncogenic action of the eIF4E translation factor (Nature 2004)
  • Winner Glaxo Smith Kline Discovery Award 
  • Member, American Society for Clinical Investigation
  • Scholar of the Leukemia and Lymphoma Society   
  • Scholar of the American Cancer Society